What's next in oncology — November 14, 2026
This issue brings together four oncology milestones with verifiable dates between November 30, 2026 and April 9, 2027: three FDA decisions (PDUFA target dates announced by the companies) and full data from two phase 3 trials at the San Antonio Breast Cancer Symposium. A PDUFA date does not guarantee approval: the FDA may approve, reject (complete response letter) or extend the review.
1. Bezuclastinib + sunitinib in second-line GIST
[Pending regulatory decision] [United States] [Confirmed date: November 30, 2026]
What it is: NDA under priority review based on PEAK (randomized, open-label phase 3, NCT05208047), 413 patients with advanced GIST who progressed on or were intolerant to imatinib, randomized to bezuclastinib + sunitinib vs sunitinib alone; median PFS by blinded central review 16.5 vs 9.2 months (HR 0.50; 95% CI 0.39–0.65) and objective response 45.6% vs 25.8% (data presented at ASCO 2026).
What problem it solves: after imatinib, the standard is sunitinib monotherapy, with limited benefit because of secondary KIT mutations; the combination aims to cover that resistance spectrum.
Critical take: open-label trial developed by Cogent, with immature OS (under 20% events, crossover allowed after centrally confirmed progression) and more liver toxicity (ALT/AST elevation 56.4% vs 16.8%; grade ≥3 10.8% vs 1.4%).
Sources
- [Official release] Cogent Biosciences, third quarter 2026 results (Exhibit 99.1 to Form 8-K filed with the SEC), November 5, 2026. https://www.sec.gov/Archives/edgar/data/0001622229/000119312526449926/cogt-ex99_1.htm
- [Registry] NCT05208047, ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT05208047
- [Official release] Cogent Biosciences, May 28, 2026. https://investors.cogentbio.com/news-releases/news-release-details/cogent-biosciences-announces-fda-acceptance-new-drug-0
- [Coverage] OncLive, May 30, 2026. https://www.onclive.com/view/bezuclastinib-plus-sunitinib-cuts-risk-of-progression-or-death-in-half-vs-sunitinib-alone-in-advanced-gist
2. SABCS 2026: full SERENA-4 data and final EMBER-3 OS
[Congress] [United States (San Antonio), global reach] [Confirmed date: December 11, 2026]
What it is: General Session 3 (symposium December 8–11) features SERENA-4 (NCT04711252; randomized, double-blind phase 3; 1,371 patients according to AstraZeneca, camizestrant + palbociclib vs anastrozole + palbociclib as first-line therapy for ER+/HER2− advanced breast cancer, primary endpoint investigator-assessed PFS) and final overall survival from EMBER-3 (imlunestrant vs standard of care in ESR1-mutated advanced breast cancer).
What problem it solves: determines whether an oral SERD should replace the aromatase inhibitor up front rather than be reserved for progression or emergence of an ESR1 mutation.
Critical take: AstraZeneca has already announced that SERENA-4 did not meet its primary PFS endpoint (with a numerical improvement, no figures released), so the presentation is for the size of the effect, subgroups and safety, not for changing the current standard.
Sources
- [Meeting] San Antonio Breast Cancer Symposium 2026, General Session 3, December 11, 2026. https://sabcs.org/events/2026/general-session-3-2/
- [Official release] AstraZeneca, September 11, 2026. https://www.astrazeneca.com/media-centre/press-releases/2026/update-serena-4-phase-iii-trial.html
- [Registry] NCT04711252, ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT04711252
3. Zanzalintinib + atezolizumab in pretreated metastatic colorectal cancer
[Pending regulatory decision] [United States] [Confirmed date: March 3, 2027]
What it is: NDA based on STELLAR-303 (randomized, open-label phase 3, NCT05425940, 901 patients without MSI-H/dMMR, vs regorafenib); median OS in the intention-to-treat population 10.9 vs 9.4 months (HR 0.80; 95% CI 0.69–0.93). The FDA extended the deadline by three months, from December 3, 2026, after classifying as a major amendment the updated data Exelixis submitted in response to an information request.
What problem it solves: in third line and beyond, the options (regorafenib, trifluridine/tipiracil ± bevacizumab, fruquintinib) offer modest benefit, and immunotherapy does not work in microsatellite-stable tumors.
Critical take: absolute gain of about 1.5 months in an open-label Exelixis trial; the co-primary endpoint in patients without liver metastases was not significant (HR 0.79; 95% CI 0.61–1.03).
Sources
- [Official release] Exelixis, Form 8-K filed with the SEC, September 11, 2026. https://www.sec.gov/Archives/edgar/data/0000939767/000093976726000108/exel-20260910.htm
- [Official release] Exelixis, February 2, 2026. https://exelixis.gcs-web.com/node/27136/pdf
- [Coverage] OncLive, September 11, 2026. https://www.onclive.com/view/fda-extends-review-period-for-zanzalintinib-plus-atezolizumab-nda-in-pretreated-mcrc
4. Rivoceranib + camrelizumab as first-line therapy for hepatocellular carcinoma
[Pending regulatory decision] [United States] [Confirmed date: April 9, 2027]
What it is: resubmission (October 9, 2026) of the rivoceranib NDA (Elevar) and camrelizumab BLA (Hengrui), under integrated review, based on CARES-310 (phase 3, NCT03764293, 543 patients, vs sorafenib): median OS 23.8 vs 15.2 months (HR 0.64; 95% CI 0.52–0.79).
What problem it solves: broadens first-line combination options (oral VEGFR inhibitor + anti-PD-1) for unresectable or metastatic hepatocellular carcinoma.
Critical take: the comparator (sorafenib) is no longer the standard against atezolizumab-bevacizumab or durvalumab-tremelimumab; this is the fourth submission after three complete response letters, and the latest (July 2026) was due, according to Elevar, to deficiencies found in a cGMP inspection of a manufacturing site, not to efficacy.
Sources
- [Registry] NCT03764293, ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT03764293
- [Coverage] Targeted Oncology, November 6, 2026. https://www.targetedonc.com/view/rivoceranib-camrelizumab-fda-pdufa-date-hcc
- [Official release] Elevar Therapeutics, November 5, 2026. https://elevartx.com/2026/11/04/elevar-fda-pdufa-new-drug-application/
- [Official release] Elevar Therapeutics, July 10, 2026. https://elevartx.com/2026/07/10/elevar-crl-july-2/
Ready-to-paste WhatsApp text
*What's next in oncology — November 14, 2026* Four milestones with verifiable dates: • Nov 30, 2026 — FDA decision on bezuclastinib + sunitinib in second-line GIST (PEAK: PFS 16.5 vs 9.2 months). • Dec 11, 2026 — SABCS: full SERENA-4 data (negative on PFS) and final EMBER-3 OS. • Mar 3, 2027 — FDA decision on zanzalintinib + atezolizumab in pretreated metastatic colorectal cancer. • Apr 9, 2027 — FDA decision on rivoceranib + camrelizumab in first-line HCC. A PDUFA date is not an approval. Full text and audio: https://boletinesmedicos.com/en/oncology/2026-11-14-viene.html MedBulletins · boletinesmedicos.com
Ready-to-paste LinkedIn post
What's next in oncology (November 2026 – April 2027), with an official source for every date: 1. November 30: FDA decides on bezuclastinib + sunitinib in GIST after imatinib (phase 3 PEAK, PFS HR 0.50; OS still immature). 2. December 11: at SABCS, full SERENA-4 data — which missed its PFS goal — and final EMBER-3 OS. 3. March 3: zanzalintinib + atezolizumab in metastatic colorectal cancer (OS gain of about 1.5 months vs regorafenib). 4. April 9: rivoceranib + camrelizumab in HCC, against a comparator that has since been superseded. Details, critical take and audio: https://boletinesmedicos.com/en/oncology/2026-11-14-viene.html #Oncology #FDA #SABCS2026 #ColorectalCancer #EvidenceBasedMedicine
Ready-to-paste X (Twitter) post
What's next in oncology: FDA decisions in GIST (Nov 30), colorectal (Mar 3) and HCC (Apr 9); full SERENA-4 at SABCS (Dec 11). https://boletinesmedicos.com/en/oncology/2026-11-14-viene.html
Get every issue by email
Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.